Brett P.  Monia net worth and biography

Brett Monia Biography and Net Worth

Dr. Monia is the chief executive officer, a member of the board of directors and a founding scientist of Ionis Pharmaceuticals. His contributions at Ionis include research into the medicinal chemistry and mechanisms of action of RNA-targeting modalities to treat human diseases, most notably antisense-based therapeutic strategies. Dr. Monia has extensive experience across a range of therapeutic areas, including oncology, metabolic disease, inflammation, neurological disease and cardiovascular disease, which have resulted in a broad range of successful clinical achievements and in marketing approvals for new medicines.

Dr. Monia has published more than 200 primary research manuscripts, reviews and book chapters, and is an inventor on more than 100 issued patents. He serves as a senior editor for the journal Nucleic Acid Therapeutics. He is on the board of directors of Cognition Therapeutics and the board of directors of Dynacure. He has also served as president of the Oligonucleotide Therapeutics Society (OTS). Dr. Monia is also an adjunct professor of biology at San Diego State University where he lectures at the graduate level on pharmacology.

Dr. Monia received his Ph.D. in Pharmacology at the University of Pennsylvania and B.S. degrees in Molecular Biology and Analytical Chemistry at Stockton State College in Pomona, New Jersey.

What is Brett P. Monia's net worth?

The estimated net worth of Brett P. Monia is at least $5.93 million as of November 12th, 2024. Dr. Monia owns 167,393 shares of Ionis Pharmaceuticals stock worth more than $5,925,712 as of November 21st. This net worth estimate does not reflect any other investments that Dr. Monia may own. Additionally, Dr. Monia receives an annual salary of $2,380,000.00 as CEO at Ionis Pharmaceuticals. Learn More about Brett P. Monia's net worth.

How old is Brett P. Monia?

Dr. Monia is currently 63 years old. There are 6 older executives and no younger executives at Ionis Pharmaceuticals. Learn More on Brett P. Monia's age.

What is Brett P. Monia's salary?

As the CEO of Ionis Pharmaceuticals, Inc., Dr. Monia earns $2,380,000.00 per year. Learn More on Brett P. Monia's salary.

How do I contact Brett P. Monia?

The corporate mailing address for Dr. Monia and other Ionis Pharmaceuticals executives is 2855 GAZELLE COURT, CARLSBAD CA, 92010. Ionis Pharmaceuticals can also be reached via phone at (760) 931-9200 and via email at [email protected]. Learn More on Brett P. Monia's contact information.

Has Brett P. Monia been buying or selling shares of Ionis Pharmaceuticals?

During the last ninety days, Brett P. Monia has sold $252,271.50 in Ionis Pharmaceuticals stock. Most recently, Brett P. Monia sold 6,630 shares of the business's stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $38.05, for a transaction totalling $252,271.50. Following the completion of the sale, the chief executive officer now directly owns 167,393 shares of the company's stock, valued at $6,369,303.65. Learn More on Brett P. Monia's trading history.

Who are Ionis Pharmaceuticals' active insiders?

Ionis Pharmaceuticals' insider roster includes Joseph Baroldi (EVP & Chief Business Officer), C. Bennett (EVP), Spencer Berthelsen (Director), Brian Birchler (EVP), Onaiza Cadoret-Manier (EVP), Breaux Castleman (Director), Stanley Crooke (Chairman), Allene Diaz (Director), Richard Geary (EVP), Elizabeth Hougen (CFO), Joseph Klein, III (Director), Brett Monia (CEO), Frederick Muto (Director), Patrick O'Neil (EVP), B. Parshall, Esq. (Director), Eugene Schneider (EVP), and Eric Swayze (EVP). Learn More on Ionis Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Ionis Pharmaceuticals?

During the last year, insiders at the sold shares 25 times. They sold a total of 270,830 shares worth more than $13,480,539.63. The most recent insider tranaction occured on November, 12th when EVP Eric Swayze sold 1,194 shares worth more than $45,276.48. Insiders at Ionis Pharmaceuticals own 2.7% of the company. Learn More about insider trades at Ionis Pharmaceuticals.

Information on this page was last updated on 11/12/2024.

Brett P. Monia Insider Trading History at Ionis Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/12/2024Sell6,630$38.05$252,271.50167,393View SEC Filing Icon  
2/16/2024Sell387$44.49$17,217.63173,751View SEC Filing Icon  
2/2/2024Sell23,501$49.37$1,160,244.37174,138View SEC Filing Icon  
1/25/2024Sell2,285$51.75$118,248.75151,851View SEC Filing Icon  
1/17/2024Sell32,059$50.42$1,616,414.78154,136View SEC Filing Icon  
12/21/2023Sell17,500$49.29$862,575.00118,111View SEC Filing Icon  
12/14/2023Sell24,000$49.58$1,189,920.00118,111View SEC Filing Icon  
10/12/2023Sell3,770$46.00$173,420.00118,111View SEC Filing Icon  
7/7/2023Sell18,650$42.25$787,962.50121,724View SEC Filing Icon  
5/22/2023Sell4,931$40.14$197,930.34140,374View SEC Filing Icon  
2/6/2023Sell24,651$40.69$1,003,049.19145,305View SEC Filing Icon  
1/18/2023Sell25,066$39.49$989,856.34120,863View SEC Filing Icon  
4/1/2022Sell355$37.49$13,308.9588,662View SEC Filing Icon  
3/1/2021Sell236$54.28$12,810.0850,350View SEC Filing Icon  
12/4/2020Sell23,840$51.04$1,216,793.6052,719View SEC Filing Icon  
12/2/2020Sell21,160$51.32$1,085,931.2050,039View SEC Filing Icon  
9/1/2020Sell314$53.70$16,861.8029,193View SEC Filing Icon  
1/2/2020Sell173$60.25$10,423.2516,285View SEC Filing Icon  
11/20/2019Sell5,776$60.01$346,617.7616,458View SEC Filing Icon  
7/2/2019Sell210$66.40$13,944.0022,444View SEC Filing Icon  
1/2/2019Sell214$53.50$11,449.0016,051View SEC Filing Icon  
11/23/2018Sell34,000$55.00$1,870,000.0049,841View SEC Filing Icon  
8/27/2018Sell16,493$54.00$890,622.0024,834View SEC Filing Icon  
7/24/2018Sell156$47.03$7,336.6815,841View SEC Filing Icon  
1/16/2018Sell2,821$51.76$146,014.9618,604View SEC Filing Icon  
1/2/2018Sell163$50.00$8,150.0011,782View SEC Filing Icon  
7/3/2017Sell309$51.35$15,867.1511,935View SEC Filing Icon  
1/17/2017Sell2,502$46.29$115,817.589,287View SEC Filing Icon  
1/3/2017Sell309$48.60$15,017.408,181View SEC Filing Icon  
12/20/2016Sell130$52.48$6,822.407,872View SEC Filing Icon  
1/4/2016Sell127$61.00$7,747.004,358View SEC Filing Icon  
6/8/2015Sell7,600$66.22$503,272.00View SEC Filing Icon  
7/31/2014Sell79$31.50$2,488.50View SEC Filing Icon  
6/11/2013Sell9,375$23.76$222,750.00View SEC Filing Icon  
See Full Table

Brett P. Monia Buying and Selling Activity at Ionis Pharmaceuticals

This chart shows Brett P Monia's buying and selling at Ionis Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Ionis Pharmaceuticals Company Overview

Ionis Pharmaceuticals logo
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
Read More

Today's Range

Now: $35.40
Low: $33.53
High: $35.60

50 Day Range

MA: $39.01
Low: $33.73
High: $42.76

2 Week Range

Now: $35.40
Low: $33.33
High: $54.44

Volume

2,223,069 shs

Average Volume

1,168,921 shs

Market Capitalization

$5.59 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.39